Company Monitoring Page for Amgen

job ratings (see below graph) for Amgen

latest headlines for company on cafepharma

Amgen’s T-Cell Engager Shows Phase II Promise in Tough to Treat Lung Cancer
BioSpace
Fri, 10/20/23 - 11:34 am
Tags:
Amgen, bispecific antibodies, T-cell engager, tarlatamab, clinical trials
Amgen Completes $27.8B Horizon Acquisition Following FTC Challenge
BioSpace
Fri, 10/6/23 - 11:37 am
Tags:
Amgen, Horizon Therapeutics, FTC, M&A
Amgen's Lumakras flunks FDA expert meeting, but market withdrawal looks unlikely for now
Fierce Pharma
Thu, 10/5/23 - 09:13 pm
Tags:
Amgen, Lumakras, FDA, KRAS inhibitors
FDA Says ‘Systemic Bias’ in Amgen’s Lumakras Trial Ahead of Adcomm Meeting
BioSpace
Wed, 10/4/23 - 11:08 am
Tags:
Amgen, Lumakras, non-small cell lung cancer, FDA
FDA staff says late-stage data 'not enough' for Amgen's lung cancer drug
Reuters
Tue, 10/3/23 - 10:23 am
Tags:
Amgen, FDA, Lumakras, lung cancer
5 FDA decisions to watch in the fourth quarter
BioPharma Dive
Mon, 10/2/23 - 12:00 pm
Tags:
FDA, Alnylam, Onpattro, ATTR amyloidosis, Vertex Pharmaceuticals, CRISPR Therapeutics, exa-cel, Bluebird Bio, Zynteglo, sickle cell disease, Bristol Myers Squibb, 2seventy bio, Abecma, Multiple Myeloma, Amgen, Lumakras, non-small cell lung cancer, Pfizer, estrasimod, ulcerative colitis
Neumora Therapeutics stock surges as Amgen confirmed as major shareholder
Proactive Investors
Thu, 09/28/23 - 10:42 am
Tags:
Amgen, Neumora, IPOs
Amgen unveils Partners of Choice oncology network
Medical Marketing and Media
Thu, 09/21/23 - 06:35 pm
Tags:
Amgen, expert panels, oncology, cancer
Amgen-Horizon Merger Clearance a Setback to FTC’s Antitrust Enforcement Plans
BioSpace
Wed, 09/20/23 - 08:59 am
Tags:
Amgen, Horizon Therapeutics, FTC, antitrust, M&A
FTC allows Amgen’s $27.8B purchase of Horizon to proceed
Medical Marketing and Media
Fri, 09/1/23 - 12:40 pm
Tags:
FTC, Amgen, Horizon Therapeutics, M&A
FTC Temporarily Withdraws Challenge to $27.8B Amgen-Horizon Deal
BioSpace
Mon, 08/28/23 - 12:06 pm
Tags:
FTC, Amgen, Horizon Therapeutics, M&A
Amgen Presents Late-Breaking Phase 2 Olpasiran Data at ESC 2023
BioSpace
Mon, 08/28/23 - 12:02 pm
Tags:
Amgen, cardiovascular disease, olpasiran, clinical trials
'Far too speculative': Amgen fights FTC's request for injunction against $28B Horizon merger
Fierce Pharma
Thu, 08/24/23 - 11:38 am
Tags:
Amgen, Horizon Therapeutics, M&A, FTC
The Biopharma Patent Cliff: 9 Drugs Losing Exclusivity by the End of 2023
BioSpace
Wed, 08/23/23 - 11:11 am
Tags:
patent cliff, patents, Takeda, Vyvanse, Pfizer, Eraxis, JNJ, Stelara, Merck, Isentress, Eiger Pharmaceuticals, Zokinvy, Astellas, Myrbetriq, Novartis, Entresto, Amgen, Otzela
KRAS crisis? FDA will gather advisers to weigh full approval for Amgen's Lumakras
Fierce Pharma
Mon, 08/21/23 - 06:56 pm
Tags:
Amgen, Lumakras, KRAS inhibitors, FDA
The 10 drugs that CMS might wrangle into negotiations
Beckers Hospital Review
Wed, 08/16/23 - 10:16 am
Tags:
CMS, Medicare, drug pricing, Bristol Myers Squibb, Janssen, Merck, Pfizer, Amgen, Boehringer Ingelheim, Pharmacyclics, AstraZeneca, Astellas, GSK
Mirati CEO Steps Down After Going Toe-to-Toe with Amgen in KRAS
BioSpace
Wed, 08/9/23 - 11:55 am
Tags:
Mirati Therapeutics, Pharma CEOs, David Meek, Amgen, KRAS inhibitors
Amgen Clinches Clinical Wins in SCLC and Colorectal Cancer
BioSpace
Fri, 08/4/23 - 12:30 pm
Tags:
Amgen, oncology, colorectal cancer, small cell lung cancer, tarlatamab, Lumakras
Amgen's hyped Humira biosimilar fritters away its exclusivity advantage
Fierce Pharma
Fri, 08/4/23 - 11:56 am
Tags:
Amgen, AbbVie, biosimilars, Humira
Amgen's tarlatamab BiTEs at small cell lung cancer in brief readout
Fierce Biotech
Thu, 08/3/23 - 06:37 pm
Tags:
Amgen, tarlatamab, small cell lung cancer, T-cells

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.